Optimizing Outpatient Care: Clinical Strategies for Managing Hepatic Encephalopathy in Primary Practice : Episode 8
AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.
EP: 1.Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families
EP: 2.Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing
EP: 3.HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading
EP: 4.Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management
EP: 5.Preventing Cirrhosis Progression: Gut-Liver Axis, Circulation, Inflammation
EP: 6.Hepatic Encephalopathy: Exploring Alterations in Microbiota Caused by Liver Disease
EP: 7.Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
Now Viewing
EP: 8.AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
EP: 9.Overview of Outpatient Strategies for Optimizing Patient Outcomes in HE
EP: 10.Managing Adverse Effects in HE Treatment
EP: 11.Practical Tips for the Primary Care Clinician Treating HE
EP: 12.Refractory Encephalopathy, Multivitamins and Closing Thoughts
- What are the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations on the treatment of patients with HE? Vilstrup et al 2014, EASL 2022
- managing covert HE
- managing overt HE
- In primary care we are somewhat familiar with rifaximin. For patients with HE, can the primary care clinician prescribe it or does the hepatologist/gastroenterologist have to prescribe it?
- What are some reasons why rifaximin is under prescribed by PCP’s?
- What are strategies to help increase uptake?
- What do we know about treatment adherence of rifaximin?
- What data do we have on the safety and efficacy of rifaximin in HE? Yu et al 2021, Zacharias et al 2023
- Alone and as combination therapy
- How do you handle payer approval, what is required?
Recent Videos
Related Content
